The FDA has cleared Intuitive Surgical's da Vinci 5 robotic system for select complex cardiac procedures, a move that could reshape the landscape of minimally invasive heart surgery and open a significant new market for the industry leader.
The FDA has cleared Intuitive Surgical's latest robotic system for use in certain heart surgeries, marking a strategic expansion into one of healthcare's largest and most complex service lines and potentially reshaping hospital capital planning for robotics.
Medtronic's expanded partnership with Mindray integrates its monitoring technologies into ASC-focused platforms, a strategic move to embed itself in a high-growth segment while analysts debate its impact on the broader investment thesis.
While fully autonomous robotic surgeons remain on the horizon, the foundational technology and data ecosystems being built today are setting the stage for a transformative shift. Two industry giants, Intuitive Surgical and Medtronic, offer investors distinct pathways to capitalize on this evolving landscape.
President Luiz Inácio Lula da Silva, 80, was discharged from a Brasília eye hospital on Friday after a successful cataract operation. The veteran leftist leader is recovering at a presidential retreat and is scheduled to return to work on Monday, amid a busy domestic and international agenda.
Brazilian President Luiz Inácio Lula da Silva was released from a São Paulo hospital Friday following a planned cataract procedure on his left eye, with his office confirming a swift return to official duties next week.
STAAR Surgical's stock fell sharply after the ophthalmic device maker announced the appointment of interim co-CEOs, fueling investor uncertainty following the CEO's recent departure and a failed takeover attempt.
Medtronic secures a key European regulatory nod for its latest pulsed field ablation catheter while deepening its collaboration with Mindray, signaling a strategic push into high-growth areas of cardiac care and ambulatory surgery.
Chinese biotech firm Arctic Vision moves to create an integrated ophthalmology powerhouse by acquiring MDCO Technology's device business, combining drug and device expertise to address unmet needs in eye care.
Glaukos shares have rebounded nearly 8% in a month, yet remain down sharply over the past year. A deep dive into the numbers reveals a stark contrast: a discounted cash flow model suggests significant upside, while price-to-sales metrics paint a picture of a richly valued stock. Investors are left weighing the promise of future glaucoma innovation against current market multiples.
Glaukos Corporation's iDose TR glaucoma therapy receives a key FDA labeling update, permitting repeat administration. While the news bolsters the company's growth narrative, analysts are divided on whether its current stock price already reflects future potential amid rich valuation metrics.
Amid a steep 60% annual share price decline, investment firm Chicago Capital has significantly reduced its position in PROCEPT BioRobotics, a developer of robotic systems for urological surgery, signaling a portfolio risk reassessment.
A Barcelona hospital has completed a groundbreaking facial transplant, the first of its kind globally where the donor offered her face as part of an assisted dying process. The recipient, who lost facial function to a severe infection, is now recovering well.
A suspected human smuggler with a prior conviction was shot by federal agents near the Arizona-Mexico border after allegedly firing at a CBP helicopter and agents during a foot pursuit, according to law enforcement officials.
The S&P 500 is home to market leaders, but not all its constituents are created equal. We examine one company navigating challenges and two others positioned for potential growth, providing context on their valuations and market positions.
While stocks priced between $10 and $50 can appear to offer an attractive balance of accessibility and maturity, their low price tags can sometimes mask underlying vulnerabilities. We examine three such companies where caution may be prudent.
The vital Rafah border crossing between Gaza and Egypt partially reopened Monday, allowing severely limited civilian movement for the first time since its capture by Israeli forces in 2024. The cautious resumption follows intense international pressure but falls far short of addressing Gaza's overwhelming humanitarian crisis.
CONMED's latest earnings reveal a strategic pivot towards higher-growth surgical platforms, moving away from slower gastroenterology lines. While sales climbed, profitability softened, setting the stage for a crucial transition year as the market weighs the company's reset valuation against its ambitious 2026 roadmap.
The Rafah border crossing between Gaza and Egypt reopened for pedestrian traffic Monday, ending a near two-year shutdown. The vital gateway, crucial for aid and movement, resumes under a complex new security framework involving Israeli oversight and international monitors.
Israel announces a limited, security-heavy reopening of Gaza's Rafah crossing with Egypt, allowing some medical evacuations while concerns mount over aid access and the safety of returnees.
